Online inquiry

IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14591MR)

This product GTTS-WQ14591MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14591MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13459MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ3346MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ15449MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ4165MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ3625MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ3042MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ15935MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ11024MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-117
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW